MDST Medicsight

TIDMMDST

RNS Number : 1237C

Medicsight Plc

02 March 2011

 
 Press Release   02 March 2011 
 

Medicsight PLC

("Medicsight" or "the Company")

Total Voting Rights

For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, the Company announces that as at 28 February 2011 the total number of ordinary shares of 5p in issue is 155,524,904, with each share carrying the right to one vote.

The Company has no ordinary shares held in treasury. The total number of voting rights in the Company is therefore 155,524,904. This figure of 155,524,904 ordinary shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

-ENDS-

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO                 Tel: +44 (0)207 605 7950 
                                   www.medicsight.com 
 Daniel Stewart & Co 
 Noelle Greenaway / Oliver Rigby   Tel: +44 (0) 207 776 
                                    6550 
                                   www.danielstewart.co.uk 
 

Media enquiries:

 
 Abchurch Communications 
                                    www.abchurch-group.com 
 Julian Bosdet                      Tel: +44 (0) 207 398 
                                     7700 
 julian.bosdet@abchurch-group.com 
 Simone Elviss                      Tel: +44 (0) 207 398 
                                     7728 
 simone.elviss@abchurch-group.com 
 Quincy Allan                       Tel: +44 (0) 207 398 
                                     7710 
 quincy.allan@abchurch-group.com 
 

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRSSDFMFFFSESD

Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Medicsight (LSE:MDST)
Historical Stock Chart
Von Jan 2024 bis Jan 2025